Literature DB >> 22552356

Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition.

Milena Perez Mak1, Verônica Torres da Costa e Silva, Regina Matsunaga Martin, Antonio Marcondes Lerario, Luis Yu, Paulo Marcelo Gehm Hoff, Gilberto de Castro.   

Abstract

PURPOSE: Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures.
METHOD: Case report. RESULT: We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO.
CONCLUSION: This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552356     DOI: 10.1007/s00520-012-1474-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan.

Authors:  Paranee Auethavekiat; Jefferson R Roberts; Timothy J Biega; Morakinyo O Toney; Reed S Christensen; Christina M Belnap; Jeffrey L Berenberg
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 2.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 3.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

4.  Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia.

Authors:  Casey L Cotant; Panduranga S Rao
Journal:  Am J Kidney Dis       Date:  2007-12       Impact factor: 8.860

5.  Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.

Authors:  Rob C M Pelger; Guus A B Lycklama A Nijeholt; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

6.  Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium.

Authors:  D J Hosking; M J Chamberlain; W R Shortland-Webb
Journal:  Br J Radiol       Date:  1975-06       Impact factor: 3.039

7.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

8.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

9.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

10.  Oncogenic osteomalacia: evidence for a humoral phosphaturic factor.

Authors:  G E Wilkins; S Granleese; R G Hegele; J Holden; D W Anderson; G P Bondy
Journal:  J Clin Endocrinol Metab       Date:  1995-05       Impact factor: 5.958

  10 in total
  9 in total

1.  Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study.

Authors:  Francesco Minisola; Cristiana Cipriani; Luciano Colangelo; Mirella Cilli; Alessandro Sciarra; Magnus Von Heland; Luciano Nieddu; Emanuela Anastasi; Roberto Pascone; Valeria Fassino; Daniele Diacinti; Flavia Longo; Salvatore Minisola; Jessica Pepe
Journal:  Endocrine       Date:  2017-06-28       Impact factor: 3.633

2.  Phosphaturic mesenchymal tumor: two contrasting cases.

Authors:  Monica C Koplas; Brian P Rubin; Murali Sundaram
Journal:  Skeletal Radiol       Date:  2014-01-09       Impact factor: 2.199

Review 3.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

4.  Metastatic prostate cancer presenting as tumour-induced osteomalacia.

Authors:  Awo Akosua K Layman; Shivam Joshi; Sanjeev Shah
Journal:  BMJ Case Rep       Date:  2019-07-16

5.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

Authors:  David E Leaf; Renata C Pereira; Hasan Bazari; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

6.  Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Authors:  Nobuaki Ito; Takuo Kubota; Sachiko Kitanaka; Ikuma Fujiwara; Masanori Adachi; Yasuhiro Takeuchi; Hitomi Yamagami; Takehide Kimura; Tatsuya Shinoda; Masanori Minagawa; Ryo Okazaki; Keiichi Ozono; Yoshiki Seino; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2021-07-13       Impact factor: 2.626

7.  Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature.

Authors:  Constantinos Savva; Jason Adhikaree; Srinivasan Madhusudan; Kamal Chokkalingam
Journal:  J Diabetes Metab Disord       Date:  2019-03-22

8.  FGF23 promotes prostate cancer progression.

Authors:  Shu Feng; Jianghua Wang; Yiqun Zhang; Chad J Creighton; Michael Ittmann
Journal:  Oncotarget       Date:  2015-07-10

Review 9.  Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease.

Authors:  Vickram Tejwani; Qi Qian
Journal:  Nutrients       Date:  2013-05-29       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.